KRAS and colorectal carcinoma: In the single-arm, phase 2 CRC cohort of the CodeBreaK 100 trial, 62 patients with KRAS G12C-mutant advanced CRC, whose disease had progressed after fluoropyrimidine, oxaliplatin, and irinotecan, were enrolled and received sotorasib monotherapy (960 mg once daily).